Interojo Inc. (KOSDAQ:119610)
South Korea
· Delayed Price · Currency is KRW 17,600
+1,400 (8.64%)
Mar 10, 2026, 12:10 PM KST
Interojo Revenue
Interojo had revenue of 32.35B KRW in the quarter ending September 30, 2025, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 109.28B, down -7.27% year-over-year. In the year 2024, Interojo had annual revenue of 115.84B, down -2.90%.
Revenue (ttm)
109.28B
Revenue Growth
-7.27%
P/S Ratio
1.69
Revenue / Employee
159.07M
Employees
687
Market Cap
184.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115.84B | -3.46B | -2.90% |
| Dec 31, 2023 | 119.30B | 1.48B | 1.25% |
| Dec 31, 2022 | 117.82B | 10.29B | 9.57% |
| Dec 31, 2021 | 107.53B | 19.33B | 21.92% |
| Dec 31, 2020 | 88.20B | -4.37B | -4.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| Jeil Pharmaceutical Co.,Ltd | 621.98B |
| JW Lifescience | 248.30B |
| iNtRON Biotechnology | 5.56B |
| Vaxcell-Bio Therapeutics | 1.90B |